Xenetic Biosciences, Inc. (NASDAQ:XBIO) Stock Short Interest Report for September

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a significant drop in short interest in September. As of September 30th, there was short interest totaling 12,868 shares, a drop of 42.7% from the September 15th total of 22,465 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 277,145 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has an average rating of “Sell”.

Xenetic Biosciences Price Performance

NASDAQ:XBIO opened at $2.11 on Thursday. The company has a 50 day moving average price of $3.18 and a 200-day moving average price of $3.05. Xenetic Biosciences has a 1-year low of $1.87 and a 1-year high of $5.28. The firm has a market cap of $4.83 million, a price-to-earnings ratio of -1.82 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%. The firm had revenue of $0.66 million for the quarter.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for oncology. The company’s research is centered on treatments for difficult-to-treat cancers, including hematologic malignancies.

Xenetic’s principal technology is XCART, a personalized chimeric antigen receptor T-cell therapy platform designed to create individualized treatments that target tumor-specific antigens on a patient’s cancer cells. The platform has been developed with an initial focus on B-cell malignancies, including multiple myeloma, where tumor heterogeneity can limit the effectiveness of conventional therapies.

The company’s activities primarily involve research, preclinical development and clinical advancement of its oncology pipeline through collaborations and strategic partnerships.